Mustang Bio, Inc., a Fortress Biotech company, is a biopharmaceutical company focused on the development of novel immunotherapies based on ground breaking Chimeric Antigen Receptor (CAR) research and gene therapies in areas of unmet need.
Mustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
Mustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference
Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme
FOX & friends interview with Fortress Biotech and Mustang Bio